{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:34:00Z","timestamp":1793126040834,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejps.2026.107675","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:32:54Z","timestamp":1790263974000},"page":"107675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of distinct bioactivation routes of clopidogrel ester analog vicagrel on CYP3A4-mediated interaction with atorvastatin in the intestine"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5697-999X","authenticated-orcid":false,"given":"Chen","family":"Ning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3525-7351","authenticated-orcid":false,"given":"Pieter","family":"Annaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejps.2026.107675_bib0050","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1124\/dmd.30.12.1497","article-title":"The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties","volume":"30","author":"Austin","year":"2002","journal-title":"Drug Metab. Dispos."},{"issue":"1\u20136","key":"10.1016\/j.ejps.2026.107675_bib0037","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.pisc.2014.02.010","article-title":"Analysis and interpretation of enzyme kinetic data","volume":"1","author":"Cornish-Bowden","year":"2014","journal-title":"Perspect. Sci."},{"issue":"5","key":"10.1016\/j.ejps.2026.107675_bib0051","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1021\/acs.biochem.7b01012","article-title":"Drug-Drug interactions between Atorvastatin and Dronedarone mediated by monomeric CYP3A4","volume":"57","author":"Denisov","year":"2018","journal-title":"Biochemistry"},{"issue":"12","key":"10.1016\/j.ejps.2026.107675_bib0048","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1592\/phco.28.12.1483","article-title":"Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects","volume":"28","author":"Farid","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.ejps.2026.107675_bib0013","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/clpt.2011.295","article-title":"A screening study of drug\u2013Drug interactions in cerivastatin users: an adverse effect of Clopidogrel","volume":"91","author":"Floyd","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.ejps.2026.107675_bib0042","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1517\/17425255.4.7.909","article-title":"Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions","volume":"4","author":"Galetin","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"3","key":"10.1016\/j.ejps.2026.107675_bib0045","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40262-022-01204-4","article-title":"Can mechanistic static models for drug-drug interactions support regulatory filing for study waivers and label recommendations?","volume":"62","author":"Gomez-Mantilla","year":"2023","journal-title":"Clin. Pharmacokinet."},{"issue":"21","key":"10.1016\/j.ejps.2026.107675_bib0027","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.ehj.2003.10.039","article-title":"Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting","volume":"25","author":"Gorchakova","year":"2004","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.ejps.2026.107675_bib0004","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1124\/dmd.109.028498","article-title":"A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel","volume":"37","author":"Hagihara","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.ejps.2026.107675_bib0052","first-page":"282","article-title":"A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro","volume":"29","author":"Ishigami","year":"2001","journal-title":"Drug Metab. Dispos."},{"issue":"11","key":"10.1016\/j.ejps.2026.107675_bib0016","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S0090-9556(24)15086-6","article-title":"Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin","volume":"28","author":"Jacobsen","year":"2000","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.ejps.2026.107675_bib0034","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0731-7085(00)00245-4","article-title":"Bioanalytical method validation design for the simultaneous quantitation of analytes that may undergo interconversion during analysis","volume":"22","author":"Jemal","year":"2000","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"6","key":"10.1016\/j.ejps.2026.107675_bib0005","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCINTERVENTIONS.111.962555","article-title":"Effect of CYP2C19\u00d72 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin","volume":"4","author":"Jeong","year":"2011","journal-title":"Circ. Cardiovasc. Interv."},{"key":"10.1016\/j.ejps.2026.107675_bib0007","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3389\/fphar.2017.00846","article-title":"Arylacetamide deacetylase is involved in vicagrel bioactivation in humans","volume":"8","author":"Jiang","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejps.2026.107675_bib0039","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1007\/s10620-008-0301-3","article-title":"A glass of water immediately increases gastric pH in healthy subjects","volume":"53","author":"Karamanolis","year":"2008","journal-title":"Dig. Dis. Sci."},{"issue":"2","key":"10.1016\/j.ejps.2026.107675_bib0003","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40262-013-0105-2","article-title":"Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases","volume":"53","author":"Karazniewicz-Lada","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2026.107675_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108991","article-title":"Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography\/angioplasty","volume":"116","author":"Karazniewicz-Lada","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.ejps.2026.107675_bib0033","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00228-019-02822-x","article-title":"Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin","volume":"76","author":"Karazniewicz-Lada","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejps.2026.107675_bib0002","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","article-title":"Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite","volume":"38","author":"Kazui","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"10","key":"10.1016\/j.ejps.2026.107675_bib0038","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1023\/A:1018923325359","article-title":"The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981","volume":"10","author":"Kearney","year":"1993","journal-title":"Pharm. Res."},{"issue":"10","key":"10.1016\/j.ejps.2026.107675_bib0012","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1124\/dmd.116.070276","article-title":"Clarification of the mechanism of clopidogrel-mediated drug-drug interaction in a clinical cassette small-dose study and its prediction based on In vitro information","volume":"44","author":"Kim","year":"2016","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.ejps.2026.107675_bib0001","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5334\/gh.1278","article-title":"World heart federation roadmap for secondary prevention of cardiovascular disease: 2023 update","volume":"19","author":"Laranjo","year":"2024","journal-title":"Glob. Heart"},{"issue":"1","key":"10.1016\/j.ejps.2026.107675_bib0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.CIR.0000047060.60595.CC","article-title":"Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction","volume":"107","author":"Lau","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ejps.2026.107675_bib0018","article-title":"Atorvastatin lactone\/acid ratios are promising biomarkers for statin dependent muscular side effects in patients with coronary heart disease","volume":"30","author":"Lauritzen","year":"2023","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"13","key":"10.1016\/j.ejps.2026.107675_bib0015","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2165\/00003088-200342130-00005","article-title":"Clinical pharmacokinetics of atorvastatin","volume":"42","author":"Lennernas","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2026.107675_bib0047","series-title":"Humans. Shanghai Institute of Materia Medica","article-title":"Metabolism and pharmacokinetics of vicagrel, a novel thienopyridine antiplatelet agent","author":"Liu","year":"2016"},{"issue":"5","key":"10.1016\/j.ejps.2026.107675_bib0041","first-page":"R254","article-title":"Calories and gastric emptying: a regulatory capacity with implications for feeding","volume":"236","author":"McHugh","year":"1979","journal-title":"Am. J. Physiol."},{"issue":"11","key":"10.1016\/j.ejps.2026.107675_bib0026","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1161\/01.CIR.0000124581.18191.15","article-title":"Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes","volume":"109","author":"Mitsios","year":"2004","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ejps.2026.107675_bib0046","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/psp4.12447","article-title":"Physiologically-based pharmacokinetic modeling of atorvastatin incorporating delayed gastric emptying and acid-to-lactone conversion","volume":"8","author":"Morse","year":"2019","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"issue":"9","key":"10.1016\/j.ejps.2026.107675_bib0040","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1021\/mp500210c","article-title":"Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state","volume":"11","author":"Mudie","year":"2014","journal-title":"Mol. Pharm."},{"issue":"18","key":"10.1016\/j.ejps.2026.107675_bib0029","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1161\/01.CIR.0000099507.32936.C0","article-title":"Effects of statins on platelet inhibition by a high loading dose of clopidogrel","volume":"108","author":"Muller","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ejps.2026.107675_bib0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijcme.2016.09.004","article-title":"Omeprazole and atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation in patients undergoing percutaneous coronary intervention in a tertiary health care system: a prospective drug\u2013drug interaction study","volume":"13","author":"Nagavi","year":"2016","journal-title":"IJC Metab. Endocr."},{"issue":"19","key":"10.1016\/j.ejps.2026.107675_bib0021","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/S0195-668X(03)00442-1","article-title":"Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function \u2014 a flow cytometry study","volume":"24","author":"Neubauer","year":"2003","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.ejps.2026.107675_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2024-003088","article-title":"Phase 1 study of novel anti-platelet agent to overcome pharmacogenomic limitations of clopidogrel","volume":"12","author":"Pareek","year":"2025","journal-title":"Open Heart"},{"issue":"17","key":"10.1016\/j.ejps.2026.107675_bib0023","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1093\/eurheartj\/ehs083","article-title":"Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study","volume":"33","author":"Park","year":"2012","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.ejps.2026.107675_bib0014","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11095-013-1158-5","article-title":"Contributions of intestine and plasma to the presystemic bioconversion of vicagrel, an acetate of clopidogrel","volume":"31","author":"Qiu","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107675_bib0035","first-page":"687","article-title":"Abundance of cytochromes P450 in human liver: a meta-analysis","volume":"57","author":"Rowland-Yeo","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.ejps.2026.107675_bib0017","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1021\/acs.molpharmaceut.5b00474","article-title":"Statin lactonization by uridine 5\u2032-diphospho-glucuronosyltransferases (UGTs)","volume":"12","author":"Schirris","year":"2015","journal-title":"Mol. Pharm."},{"issue":"18","key":"10.1016\/j.ejps.2026.107675_bib0030","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1001\/archinte.164.18.2051","article-title":"Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study","volume":"164","author":"Serebruany","year":"2004","journal-title":"Arch. Intern. Med."},{"issue":"7","key":"10.1016\/j.ejps.2026.107675_bib0006","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1021\/jm300038c","article-title":"Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent","volume":"55","author":"Shan","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2026.107675_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.738562","article-title":"The dynamic effect of non-CYP3A4-metabolized and CYP3A4-metabolized statins on clopidogrel resistance in patients with cerebral infarction","volume":"12","author":"Shi","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"4\u20135","key":"10.1016\/j.ejps.2026.107675_bib0053","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejps.2007.12.009","article-title":"Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro","volume":"33","author":"Skottheim","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"issue":"22","key":"10.1016\/j.ejps.2026.107675_bib0019","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIR.0b013e318235eb4d","article-title":"AHA\/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American college of cardiology foundation","volume":"124","author":"Smith","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ejps.2026.107675_bib0024","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.avsg.2023.05.023","article-title":"Atorvastatin effect on clopidogrel efficacy in patients with peripheral artery disease","volume":"95","author":"Suarez Ferreira","year":"2023","journal-title":"Ann. Vasc. Surg."},{"issue":"4","key":"10.1016\/j.ejps.2026.107675_bib0011","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/clpt.2014.141","article-title":"Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions","volume":"96","author":"Tornio","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.ejps.2026.107675_bib0031","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1160\/TH05-01-0046","article-title":"The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease","volume":"94","author":"Vinholt","year":"2005","journal-title":"Thromb. Haemost."},{"issue":"Pt 4","key":"10.1016\/j.ejps.2026.107675_bib0009","article-title":"Promising clopidogrel analogs may overcome clopidogrel resistance: 2025 update","volume":"242","author":"Xie","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejps.2026.107675_bib0049","article-title":"GW24-e2267\u2005Atorvastatin decrease the active thiol metabolite of clopidogrel when it is administered concomitantly in healthy Chinese volunteers","volume":"99","author":"Yan","year":"2013","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.ejps.2026.107675_bib0043","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1124\/dmd.106.013359","article-title":"Misuse of the well-stirred model of hepatic drug clearance","volume":"35","author":"Yang","year":"2007","journal-title":"Drug Metab. Dispos."},{"issue":"7","key":"10.1016\/j.ejps.2026.107675_bib0044","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/138920007782109733","article-title":"Prediction of intestinal first-pass drug metabolism","volume":"8","author":"Yang","year":"2007","journal-title":"Curr. Drug Metab."},{"issue":"2","key":"10.1016\/j.ejps.2026.107675_bib0022","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1476-5381.2010.00881.x","article-title":"Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro","volume":"161","author":"Zahno","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejps.2026.107675_bib0008","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/bdd.2340","article-title":"Vicagrel is hydrolyzed by Raf kinase inhibitor protein in human intestine","volume":"43","author":"Zhu","year":"2022","journal-title":"Biopharm. Drug Dispos."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726002496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726002496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:54:53Z","timestamp":1793123693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726002496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":52,"alternative-id":["S0928098726002496"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107675","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of distinct bioactivation routes of clopidogrel ester analog vicagrel on CYP3A4-mediated interaction with atorvastatin in the intestine","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107675"}}